AU701790B2 - Method for treating cancers using 6-{3-{1-adamantyl}- 4-hydroxyphenyl} - Google Patents

Method for treating cancers using 6-{3-{1-adamantyl}- 4-hydroxyphenyl} Download PDF

Info

Publication number
AU701790B2
AU701790B2 AU64949/96A AU6494996A AU701790B2 AU 701790 B2 AU701790 B2 AU 701790B2 AU 64949/96 A AU64949/96 A AU 64949/96A AU 6494996 A AU6494996 A AU 6494996A AU 701790 B2 AU701790 B2 AU 701790B2
Authority
AU
Australia
Prior art keywords
ahpn
cells
cell
breast cancer
mda
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU64949/96A
Other languages
English (en)
Other versions
AU6494996A (en
Inventor
Joseph A. Fontana
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Galderma Research and Development SNC
Original Assignee
Centre International de Recherches Dermatologiques Galderma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre International de Recherches Dermatologiques Galderma filed Critical Centre International de Recherches Dermatologiques Galderma
Publication of AU6494996A publication Critical patent/AU6494996A/en
Application granted granted Critical
Publication of AU701790B2 publication Critical patent/AU701790B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AU64949/96A 1995-07-17 1996-07-17 Method for treating cancers using 6-{3-{1-adamantyl}- 4-hydroxyphenyl} Ceased AU701790B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US146595P 1995-07-17 1995-07-17
US60/001465 1995-07-17
PCT/US1996/011736 WO1997003682A1 (en) 1995-07-17 1996-07-17 Method for treating cancers using 6-[3-[1-adamantyl]-4-hydroxyphenyl]

Publications (2)

Publication Number Publication Date
AU6494996A AU6494996A (en) 1997-02-18
AU701790B2 true AU701790B2 (en) 1999-02-04

Family

ID=21696159

Family Applications (1)

Application Number Title Priority Date Filing Date
AU64949/96A Ceased AU701790B2 (en) 1995-07-17 1996-07-17 Method for treating cancers using 6-{3-{1-adamantyl}- 4-hydroxyphenyl}

Country Status (5)

Country Link
EP (1) EP0850067A4 (ja)
JP (1) JP2000506489A (ja)
AU (1) AU701790B2 (ja)
CA (1) CA2223489A1 (ja)
WO (1) WO1997003682A1 (ja)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2739557B1 (fr) * 1995-10-09 1997-11-14 Cird Galderma Utilisation d'un ligand agoniste specifique rar-gamma
US6462064B1 (en) 1996-07-08 2002-10-08 Galderma Research & Development S.N.C. Apoptosis inducing adamantyl derivatives and their usage as anti-cancer agents, especially for cervical cancers and dysplasias
RU2209626C2 (ru) * 1996-07-08 2003-08-10 Галдерма Ресерч энд Девелопмент, С.Н.С. Производные адамантила, вызывающие апоптоз, и их использование в качестве противораковых агентов
EA200200311A1 (ru) 1999-08-31 2002-08-29 Максиа Фармасьютикалз, Инк. Бензилиден-тиазолидиндионы и аналоги и их применение для лечения диабета
MXPA03008117A (es) 2001-03-07 2004-11-12 Incyte San Diego Inc Derivados heterociclicos para el tratamiento del cancer y otras enfermedades proliferativas.
CA2473156A1 (en) 2001-03-08 2002-09-19 Incyte San Diego, Inc. Rxr activating molecules
DE10255861A1 (de) * 2002-11-29 2004-06-17 Axxima Pharmaceuticals Ag Gegen Hepatitis C-Virusinfektionen nützliche Verbindungen und Substanzen
KR100453877B1 (ko) 2001-07-26 2004-10-20 메덱스젠 주식회사 연쇄체화에 의한 면역 글로블린 융합 단백질의 제조 방법 및 이 방법에 의해 제조된 ＴＮＦＲ/Ｆｃ 융합 단백질, 상기 단백질을 코딩하는 ＤＮＡ, 상기 ＤＮＡ를 포함하는벡터, 및 상기 벡터에 의한 형질전환체
EP1456187A4 (en) 2001-11-15 2005-02-09 Incyte San Diego Inc N-SUBSTITUTED HETEROCYCLES FOR THE TREATMENT OF HYPERCHOLESTERINEMIA, DYSLIPIDEMIA AND OTHER METABOLIC DISORDER, CANCER AND OTHER DISEASES
US7196108B2 (en) 2002-03-08 2007-03-27 Incyte San Diego Inc. Bicyclic heterocycles for the treatment of diabetes and other diseases
US7102000B2 (en) 2002-03-08 2006-09-05 Incyte San Diego Inc. Heterocyclic amide derivatives for the treatment of diabetes and other diseases
JP2006514094A (ja) * 2002-11-29 2006-04-27 ゲーペーツェー バイオテック アクチェンゲゼルシャフト Ｃ型肝炎ウイルス感染に対して有用な製剤
US20090117203A1 (en) * 2006-03-23 2009-05-07 Tmrc Co., Ltd. Kit for cancer treatment and pharmaceutical composition for cancer treatment
WO2007148804A1 (ja) * 2006-06-23 2007-12-27 Rohto Pharmaceutical Co., Ltd. ヒアルロン酸産生促進能を有する組成物
EP3301085A1 (en) 2016-09-29 2018-04-04 Biogem S.Ca.R.L. Retinoid derivatives with antitumor activity
WO2022229017A1 (en) 2021-04-27 2022-11-03 Biogem S.C.A R.L. Adamantyl retinoid derivative with anticancer activity

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4717720A (en) * 1985-04-11 1988-01-05 Centre International De Recherches Dermatologiques (C.I.R.D.) Benzonaphthalene derivatives and compositions

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4717720A (en) * 1985-04-11 1988-01-05 Centre International De Recherches Dermatologiques (C.I.R.D.) Benzonaphthalene derivatives and compositions

Also Published As

Publication number Publication date
EP0850067A4 (en) 1999-12-15
AU6494996A (en) 1997-02-18
WO1997003682A1 (en) 1997-02-06
EP0850067A1 (en) 1998-07-01
JP2000506489A (ja) 2000-05-30
CA2223489A1 (en) 1997-02-06

Similar Documents

Publication Publication Date Title
AU701790B2 (en) Method for treating cancers using 6-{3-{1-adamantyl}- 4-hydroxyphenyl}
Bertram et al. Cancer prevention by retinoids and carotenoids: independent action on a common target
EP0804194B1 (en) Use of retinoic acid receptor-agonists or ap-1 antagonists for the manufacture of a medicament for preventing proliferation of retinal pigment epithelium
US6130230A (en) Therapeutic combinations of RAR antagonists and RXR agonists and use thereof
Iniguez et al. Induction of cyclooxygenase-2 on activated T lymphocytes: regulation of T cell activation by cyclooxygenase-2 inhibitors
Campbell et al. Expression of retinoic acid receptor-β sensitizes prostate cancer cells to growth inhibition mediated by combinations of retinoids and a 19-nor hexafluoride vitamin D3 analog
US5821254A (en) Uses of 9-cis-retinoic acids and derivatives thereof alone or in combination with antineoplastic agents in the prevention or treatment of cancer
De los Santos et al. Combined effects of retinoic acid and histone deacetylase inhibitors on human neuroblastoma SH-SY5Y cells
Rigas et al. Emerging role of rexinoids in non-small cell lung cancer: focus on bexarotene
US20090093546A1 (en) Method and Pharmaceutical Compositions for Treatment of Anti-Estrogen Resistant Breast Cancer Using RXR Modulators
WO2008144475A1 (en) Methods and compositions for treating cancer
WO1998008546A9 (en) Therapeutic combinations of rar antagonists and rxr agonists and use thereof
Hamada et al. Phase I/II study of the oral retinoid X receptor agonist bexarotene in Japanese patients with cutaneous T‐cell lymphomas
Kim et al. Rosiglitazone promotes tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by reactive oxygen species-mediated up-regulation of death receptor 5 and down-regulation of c-FLIP
US6211239B1 (en) Method for treating or preventing breast cancer or leukemia using 6-[3-[1-adamantyl]-4-hydroxyphenyl]-2-naphthalene carboxylic acid (AHPN)
Campbell et al. Synergistic inhibition of prostate cancer cell lines by a 19-nor hexafluoride vitamin D3 analogue and anti-activator protein 1 retinoid
WO2000053198A1 (en) Inhibitor of lipoxygenase pathways
US20040122080A1 (en) Synergist combinations of retinoid receptor ligands and selected cytotoxic agents for treatment of cancer
Amanzadeh et al. New synergistic combinations of differentiation-inducing agents in the treatment of acute promyelocytic leukemia cells
Muñiz-Hernández et al. Alterations in retinoic acid receptors in non-small cell lung cancer and their clinical implications
US20020090352A1 (en) Compositions and methods for use in modulating immune system function
Tsiklakis et al. The therapeutic effect of an aromatic retinoid (RO-109359) on hamster buccal pouch carcinomas
Pandey et al. RXRα: Novel Target for Prostate Cancer
KR20030086314A (ko) 암 치료를 위한 레티노이드 수용체 리간드 및 선별된세포독성제의 상승적 조합
Nabiuni et al. 41. Anti-Inflammatory Effect of Honey Bee Venom on Wistar Rats Induced Poly Cystic Ovarian Syndrome by Estradiol Valerate

Legal Events

Date Code Title Description
MK14 Patent ceased section 143(a) (annual fees not paid) or expired